Myofibroblasts are a key cell type in wound repair, cardiovascular disease, and fibrosis and in the tumor-promoting microenvironment. The high accumulation of myofibroblasts in reactive stroma is predictive of the rate of cancer progression in many different tumors, yet the cell types of origin and the mechanisms that regulate proliferation and differentiation are unknown. We report here, for the first time to our knowledge, the characterization of normal human prostate-derived mesenchymal stem cells (MSCs) and the TGF-β1-regulated pathways that modulate MSC proliferation and myofibroblast differentiation. Human prostate MSCs combined with prostate cancer cells expressing TGF-β1 resulted in commitment to myofibroblasts. TGF-β1-regulated runt-related transcription factor 1 (RUNX1) was required for cell cycle progression and proliferation of progenitors. RUNX1 also inhibited, yet did not block, differentiation. Knockdown of RUNX1 in prostate or bone marrow-derived MSCs resulted in cell cycle arrest, attenuated proliferation, and constitutive differentiation to myofibroblasts. These data show that RUNX1 is a key transcription factor for MSC proliferation and cell fate commitment in myofibroblast differentiation. This work also shows that the normal human prostate gland contains tissue-derived MSCs that exhibit multilineage differentiation similar to bone marrow-derived MSCs. Targeting RUNX1 pathways may represent a therapeutic approach to affect myofibroblast proliferation and biology in multiple disease states.
M
yofibroblasts are key mediators of homeostasis-associated biology in reactive stroma associated with tissue repair, fibrosis, and the tumor microenvironment. However, the specific cell types of origin and the mechanisms that regulate their activation, proliferation, and differentiation are not understood. Accordingly, identifying the niche and origins of myofibroblasts and pathways that regulate their proliferation and commitment to myofibroblasts is important to developing antifibrotic and anticancer therapeutic approaches designed to target the evolution and proliferation of myofibroblasts.
Adult mesenchymal stem cells (MSCs) are defined as multipotent stromal cells capable of self-renewal and differentiation to cartilage, bone, and adipose tissues (1) . Studies have primarily addressed the biology of marrow-derived MSCs and far less is understood about putative tissue-resident MSCs and how they contribute to the biology of their tissue of residence. Recent evidence from mouse models implicates tissue-resident MSCs in repair processes of disrupted local tissue homeostasis, suggesting that they are a critical component in wound repair, fibrosis, cardiovascular disease, and in the tumor microenvironment (2) . Each of these is associated with evolution of reactive stroma with expression of repair-centric genes. However, very little is known about adult human tissue-resident MSCs and the mechanisms that regulate their proliferation and lineage commitment to local reactive stroma or fibrotic tissue.
Reactive stroma is dynamic and responds rapidly to emerging situations to restore disrupted homeostasis (3, 4) . Reactive stroma is found in most cancers and is typified by the coevolution of myofibroblasts (5) (6) (7) . Importantly, the volume of reactive stroma relative to cancer is predictive of the rate of cancer progression in several tumor types (8) (9) (10) (11) (12) (13) (14) (15) . Furthermore, in vivo modeling has shown that reactive stroma is tumor-promoting (16) (17) (18) (19) . The myofibroblast is the principal cell type in reactive stroma, and transforming growth factor beta 1 (TGF-β1) is a potent inducer of myofibroblast differentiation (3, 20) . TGF-β1 is overexpressed in most human cancers, including prostate cancer (2, 7) . However, the cell types of origin and mechanisms that regulate their proliferation and differentiation to myofibroblasts remain unknown.
To address tissue-resident MSCs in the prostate gland and their potential induction to myofibroblasts, we have evaluated whether tissue-associated MSCs reside in normal adult human prostate tissue, whether they are induced to become myofibroblasts by TGF-β1, and the key mechanisms that regulate their proliferation. We report here for the first time, to our knowledge, the isolation of cells with prototypical MSC properties derived from normal adult human prostate gland. These cells exhibit multipotent differentiation similar to bone marrow-derived MSCs and form typical reactive stroma myofibroblasts under TGF-β1 regulation. Importantly, we have identified runt-related transcription factor 1 Significance Recruitment, proliferation, and differentiation of myofibroblasts are common in many disease states. Mechanisms that regulate proliferation and differentiation are poorly understood, although TGF-β is a key inducer of differentiation. Here, we report, for the first time to our knowledge, that runt-related transcription factor 1 (RUNX1) regulates mesenchymal stem cell (MSC) biology and progenitor cell commitment to myofibroblasts. In this work, we describe the first identification, to our knowledge, of tissue-resident MSCs from adult normal human prostate gland and the role of these MSCs as myofibroblast precursors. We also pinpoint the role of RUNX1 in regulating proliferation and differentiation in both marrow-derived and tissue-resident MSCs. Perturbation of RUNX1 activity may provide insights for developing antifibrotic and anticancer therapies via targeting the reactive stroma microenvironment.
(RUNX1) as a key transcription factor that is required for MSC/ progenitor cell proliferation and that functions to moderate myofibroblast differentiation.
Results
Prostate-Derived CD44 +
CD90
+ Cells Are Functional Mesenchymal Stem Cells. Fresh tissue cores from the peripheral zone of normal human prostate glands were obtained from 19-y-old (HPS-19I cells) and 33-y-old (HPS-33Q cells) cadaver donors with no prostate gland histopathology and explants cultured in a selective medium and protocol optimized for the culture of fetal rodent urogenital sinus mesenchyme (21) . The resulting monolayers were evaluated for phenotypic markers and biology. Both HPS-19I and HPS-33Q cells exhibited spindle-shaped fibroblast-like morphology ( Fig. 1A ) and were capable of long-term culture for more than 25 passages, indicating a long-term growth potential. These cells exhibited density-dependent inhibition of cell growth when reaching more than 70% confluency, which restricted subsequent passage efficiency and differentiation potential. Both HPS-19I and HPS-33Q cells exhibited a normal diploid karyotype and lacked chromosomal aberrations, including translocations as indicated by spectral karyotyping (SI Appendix, Fig. S1 ). Flow cytometry showed that both cell lines were positive for CD44 and CD90 ( 
+ dual positive cells and individual cells were localized in the stromal compartment (Fig.  1C) . In addition, dual positive immunoreactivity was observed in small vessels of the microvasculature and nerves. Although many fields exhibited a density of 1% or lower, the average density was 2.83% of total cells (SI Appendix, Fig. S2 ).
Owing to the expression of MSC-associated markers, longterm passage potential, and diploid status, we addressed whether these cells exhibit multipotent MSC characteristics. To address multilineage differentiation potential, HPS-19I and HPS-33Q cells were evaluated relative to human bone marrow-derived MSCs (hBM-MSCs). HPS-19I cells were induced to differentiate into neurogenic, chondrogenic, and osteogenic lineages (Fig. 1D ), but were restricted from adipogenic differentiation. hBM-MSCs differentiated into all four lineages (SI Appendix, Fig. S3A ). HPS-33Q cells could be induced to chondrocytes (SI Appendix, Fig. S3B ), whereas osteogenic induction was less clear. Expression profiles of MSC-specific markers and stem cell markers in HPS-19I cells were congruent with profiles in hBM-MSCs (Fig. 1F) . Moreover, flow cytometry revealed that the cell lines HPS-19I, HPS-33Q, and hBM-MSCs were each positive for CD44, CD90, CD13, CD29, CD73, and CD105, the most commonly reported human MSC markers, and were low for CD106 and STRO-1 (Fig. 1 E and G) . Based on specific morphology, plastic adherence, multipotency, transcriptome, and cell-surface protein profiles of HPS-19I and HPS-33Q cells, we hereafter refer to these cells collectively as human prostate-derived mesenchymal stem cells (hP-MSCs).
Carcinoma hP-MSC Cell Interactions in 3D Organoid Cultures. A 3D organoid coculture system in defined medium that permitted the study of cell-cell interactions and differentiation potentials was developed ( Fig. 2A) . A combination of LNCaP human prostate carcinoma cells with hP-MSCs resulted in free-floating self-organizing organoids exhibiting a central core of hP-MSCs and an outer mantel of LNCaP (Fig. 2B ). Organoids constructed with LNCaP and hBMMSCs exhibited an identical phenotype (SI Appendix, Fig. S4A ). IHC of 3D organoids showed that the core of hP-MSCs was positive for CD44 and CD90 and that the LNCaP mantel was positive for androgen receptor (AR) (Fig. 2C) . LNCaP or hP-MSCs seeded alone also self-organized as a free-floating 3D organoid (SI Appendix, Fig.  S4A ) and could be indirectly cocultured with other cells as monolayers. Combination of LNCaP and hP-MSCs inoculated as s.c. xenografts in nude mice exhibited a similar self-organization in vivo with typical carcinoma foci and adjacent stroma ( Fig. 2B ; SI Appendix, Fig. S4B) .
To investigate the function of TGF-β1 and hP-MSCs in the genesis of reactive stroma, hP-MSCs were cocultured with LNCaP engineered to express constitutively active TGF-β1 (SI Appendix, Fig. S6A ). Organoids constructed with TGF-β1-expressing LNCaP exhibited elevated immunoreactivity for α-smooth muscle actin (α-SMA) and tenascin-C in hP-MSCs relative to control (Fig. 2D) . Both are prototypical markers of reactive stroma myofibroblasts (7) . Tenascin-C was predominantly localized in stroma immediately adjacent to epithelial cells, similar to patterns noted in human prostate disease (7) . In addition, hP-MSCs exhibited increased immunoreactivity for both vimentin and fibroblast activation protein (FAP) under TGF-β1-stimulated conditions (SI Appendix, Fig.  S5A ). Furthermore, in vivo xenografts (day 11) generated with hPMSCs combined with LNCaP resulted in a central core of α-SMApositive myofibroblasts (SI Appendix, Fig. S4C ). Labeling of the hP-MSCs via expression of RFP marker protein showed RFP and α-SMA dual positive cells in combined xenografts (day 10) (SI Appendix, Fig. S13 ).
TGF-β1-Induced Gene Expression Profiles of hP-MSCs Exhibit a
Reactive Stroma Myofibroblast Signature. To identify gene expression profile alterations, we analyzed indirect cocultures of hP-MSC and engineered LNCaP organoids ( Fig. 2A) . ELISA analysis confirmed that active TGF-β1 was observed only in cocultures made with TGF-β1-expressing LNCaP (SI Appendix, Fig. S6B ). hP-MSCs cocultured with LNCaP expressing TGF-β1 exhibited an increased expression of reactive stroma genes such as TNC, ACTA2, FAP, and COL1A1 and showed distinct gene profiles including genes encoding cell-surface markers and growth factors important in stromal-epithelial interactions, including CTGF, IGF1, BMP6, IL8, IL6, WNT5A, and WNT11 ( Fig. 2E ; SI Appendix, Fig. S7 ). Several pathway-focused PCR arrays revealed differential regulation of genes involved in a range of biological processes likely to be important in carcinoma-myofibroblast interactions (SI Appendix, Dataset S1). Direct-contact monolayer cocultures and 3D organoids were also analyzed to assess how cell-to-cell contact affects gene expression. Direct cocultures of RFP + hP-MSCs and GFP + -engineered LNCaP showed that fluorescent-activated cell sorting (FACS)-sorted hP-MSCs exhibited a similar TGF-β1-regulated gene expression profile as in the indirect cocultures (SI Appendix, Fig. S8 ). Furthermore, laser capture microdissection was used to harvest RNA from hP-MSCs in 3D organoids with TGF-β1-expressing LNCaP. hP-MSCs in 3D organoids exhibited a distinct reactive stroma gene signature (SI Appendix, Fig. S5B ), consistent with the protein expression data ( Fig. 2D ; SI Appendix, Fig.  S5A ). In addition, PC3 human prostate cancer cells naturally express and secrete latent TGF-β1. Conditioned media from PC3 cells (TGF-β activated by acid) induced a nearly identical gene expression pattern in hP-MSCs, as observed with engineered LNCaP, and this response was abrogated by SD208, a TGF-β type I receptor blocker (SI Appendix, Fig. S9 ). Together, these results further support the concept that TGF-β1-expressing prostate cancer cells induce hP-MSCs to a myofibroblast differentiation pattern and mediate the reactive stromal response via altered expression of a wide range of growth factors and cytokines.
Transcription Factors Associated with MSC Proliferation and
Myofibroblast Differentiation. To better understand mechanisms that may regulate proliferation and myofibroblast differentiation, transcription factor-focused PCR arrays were used to identify candidate genes. Gene expression analysis of hP-MSCs from indirect cocultures showed differential regulation of transcription factor expression (SI Appendix, Dataset S2). qRT-PCR analysis was performed to validate the top six major transcription factors upregulated by TGF-β1-expressing LNCaP in hP-MSCs (SI Appendix, Fig. S10 ). From this analysis, we further evaluated RUNX1 and its binding partner CBFB, as well as ID1, as these exhibited higher expression levels relative to the other upregulated genes. Each of these was verified as being TGF-β1-regulated in hP-MSCs ( Fig. 2E ; SI Appendix, Figs. S7 and S8B). Consistent with increased mRNA, hP-MSCs treated with TGF-β1 also exhibited elevated expression of RUNX1 protein (SI Appendix, Fig. S11 ). RUNX1 has been identified as a key transcription factor required for definitive hematopoiesis by regulating stem/progenitor cell proliferation and differentiation (22) . RUNX1 is also reported to be involved in chondrocyte differentiation (23) and was shown to be a target of TGF-β signaling (24) . These findings prompted us to further study a potential functional role of RUNX1 in MSC biology and differentiation to myofibroblasts.
Inhibition of RUNX1 Promotes Myofibroblast Differentiation. Immunofluorescent staining of RUNX1 with or without TGF-β1 treatment in hP-MSCs showed nuclear RUNX1 expression only after TGF-β1 induction, suggesting that TGF-β1 induces nuclear accumulation of RUNX1 (Fig. 3A) . To elucidate the role of RUNX1 in myofibroblast differentiation, RUNX1 expression in hP-MSCs was attenuated using two different siRNAs ( Fig. 3B ; SI Appendix, Figs. S12A and S14A). The prototypical genes associated with myofibroblasts, ACTA2 and TNC, exhibited a dramatic increase in RUNX1 knockdown conditions ( Fig. 3D ; SI Appendix, Fig. S12B ). Suppression of RUNX1 also increased BMP6 and PTGS2 (also known as COX2) but not WNT11 ( Fig. 3D ; SI Appendix, Fig. S12B ). Under coculture conditions with LNCaP expressing TGF-β1, an even greater increase in myofibroblast-associated genes was observed ( Fig. 3D ; SI Appendix, Fig. S12B ). Engineered Note that depletion of RUNX1 exhibited a myofibroblast signature in hP-MSCs, which was augmented by TGF-β1. Data represent mean ± SEM. n = 3; *P < 0.05; **P < 0.01; ***P < 0.001.
overexpression of RUNX1 (Fig. 3C ) produced no significant increase or decrease in the effect of TGF-β1 on hP-MSCs (Fig.  3D ). These results suggest that RUNX1 is permissive for myodifferentiation but may restrict complete differentiation, perhaps by maintenance of a proliferative (progenitor) status. Accordingly, we next evaluated the role of RUNX1 in mediating proliferation of MSCs.
RUNX1 Is Required for MSC Cell Cycle Progression and Proliferation.
Knockdown of RUNX1 altered cell morphology. hP-MSCs with RUNX1 knockdown exhibited a more spread out, large, and flattened phenotype (Fig. 4A ). Consistent with this phenotype, RUNX1 knockdown resulted in decreased CD44, POU5F1 (also known as OCT4), and BMP2 expression, yet maintained THY1 (also known as CD90) expression ( Fig. 4B ; SI Appendix, Fig. S14B ). THY1 is a known marker of prostate cancer-associated fibroblasts (25) . Of most interest, hP-MSCs with RUNX1 knockdown were restricted from proliferation ( Fig. S15 ). These data suggest that attenuated RUNX1 restricts proliferation by modulating cell cycle regulators without inducing cell death. RUNX1 knockdown in marrow-derived MSCs produced nearly identical results. These cells also exhibited a more flattened phenotype and were fully growth restricted under RUNX1 knockdown conditions (Fig. 5A) . In a similar manner, the percentage of cells in S phase was reduced (Fig. 5E) . Expression of proliferation-associated genes and cell cycle control genes ( Fig. 5 B and D) , as well as differentiation/stemness-associated genes (Fig. 5C ) exhibited a pattern consistent with those observed in hP-MSCs.
To assess how RUNX1 expression affects cell proliferative or differentiation-committed states, we examined the localization of RUNX1, Ki-67, and α-SMA after RUNX1 knockdown in both hPMSCs and hBM-MSCs. Cell morphology changes and α-SMA expression were correlated with the nuclear intensity of RUNX1 staining (Fig. 6A) . In control hP-MSCs, small and undifferentiated cells showed higher RUNX1 nuclear staining and lower α-SMA cytoplasmic expression (arrowheads) than large and differentiated cells (arrows). More interestingly, RUNX1-depleted hP-MSCs and hBM-MSCs revealed a myofibroblast phenotype characterized by actin polymerization, whereas controls expressed nonpolymerized actin. A similar correlation to that seen between RUNX1 and α-SMA was observed between Ki-67 and α-SMA (Fig. 6B ). An increase in α-SMA in MSCs corresponded to loss of Ki-67 expression and morphology changes consistent with myofibroblast differentiation. Ki-67 negative cells in RUNX1 knockdown MSCs exhibited highly organized α-SMA (arrows). In addition, in vivo xenografts (day 3) constructed with LNCaP cells combined with RFP-expressing control or RUNX1 knockdown hP-MSCs also showed reduced Ki-67 staining in RUNX1 knockdown conditions (SI Appendix, Fig. S16 ). Consistent with these data, xenografts constructed with RUNX1 knockdown hP-MSCs exhibited a greater staining intensity for α-SMA (SI Appendix, Fig. S13 ). Overall, these results suggest that RUNX1 in MSCs is required for cell proliferation and modulates terminal differentiation to myofibroblasts (Fig. 6C ).
Discussion
We report the first (to our knowledge) isolation and characterization of tissue-resident MSCs derived from human normal adult prostate gland (21) . The prostate-derived MSCs exhibited MSCtypical cell-surface antigen profiles and were multipotent and capable of long-term culture. Previous reports of adult human tissueresident MSCs are restricted to dental (29) , adenoid (30) , and adipose (31) tissues. Importantly, we report here a critical role of RUNX1 in modulating MSC cell proliferation and committed differentiation to myofibroblasts. Myofibroblasts are stromal cells that are crucial for proper wound repair and the formation of reactive stroma associated with cancer, fibrosis, and vessel disease. Our data suggest that prostate-resident CD44 +
CD90
+ MSCs are one potential source of reactive stroma myofibroblasts that coevolve with foci of prostate cancer and in benign prostatic hyperplasia. There are several reported sources of myofibroblasts and carcinoma associated fibroblasts in tumor-associated reactive stroma, including circulating MSCs, normal fibroblasts, circulating fibrocytes, and vessel-associated pericytes (1, 2, 32, 33) . Our data do not exclude the involvement of these cell types. Our data further show that RUNX1 is an essential transcription factor for MSC proliferation and that RUNX1 modulates MSC differentiation to myofibroblasts. TGF-β1, overexpressed by prostate carcinoma cells, is a key inducer of myofibroblast differentiation and biology. We show here that RUNX1 expression is regulated by TGF-β1 in MSCs and that RUNX1 affects TGF-β1-stimulated gene expression during differentiation to myofibroblasts.
Myofibroblasts are important in normal wound closure and contribute to the pathology of several diseases and disorders. Importantly, myofibroblasts provide a prowound repair environment that forms granulation tissue and contracts to affect wound closure. The transient appearance of myofibroblasts is beneficial in restoring and maintaining tissue homeostasis. However, excessive myofibroblast proliferation and prolonged presence is detrimental for tissue function and thereby increases the risk of fibrotic diseases and cancers in many tissues including lung, liver, kidney, and prostate (4, For C, data represent mean ± SD; two-way ANOVA. n = 3; *P < 0.05; **P < 0.01; ***P < 0.001.
34, 35)
. Thus, reactive stroma is associated with elevated accumulation of myofibroblasts, a hallmark of fibrosis and a predictor of cancer progression. Accordingly, identifying mechanisms that affect the genesis of myofibroblasts from precursor cells may provide potential therapeutic targets in the treatment of fibrotic diseases and cancers.
RUNX1 is a key transcription factor that regulates hematopoietic stem cells and hematopoiesis (36) ; however, its role in MSC and myofibroblast biology has not been reported. Our data show that RUNX1 expression is required for extended self-renewal and proliferation of MSCs and that RUNX1 expression is stimulated by TGF-β1. Attenuation of RUNX1 induced complete myofibroblast differentiation and quiescence of hP-MSCs, and this was potentiated by TGF-β1. Interestingly, these data show that TGF-β1 induces expression of genes associated with differentiation of myofibroblasts, yet also stimulates expression of RUNX1 that inhibits differentiation and maintains proliferation. The genesis of reactive stroma myofibroblasts depends on the proliferation of MSCs and their transit-amplifying progeny. Hence, one possible explanation for our data is that TGF-β1 induces MSC commitment to myofibroblast progenitor cells while maintaining proliferative status via elevated or sustained expression of RUNX1. This concept is consistent with previous reports that show that TGF-β1 stimulates proliferation of mesenchymal stem cells (37) (38) (39) , progenitor cells, and several types of fibroblasts (40) (41) (42) (43) and also induces myofibroblast differentiation and the fibrosis phenotype (44) . TGF-β has been shown to stimulate fibroblast proliferation and subsequently induce their quiescence and differentiation to myofibroblasts in a coordinate manner (45) . Additional factors, including CXCL12 (SDF-1), have also been shown to regulate the myofibroblast phenotype (46) . TGF-β and CXCL12 pathways interact and regulate accumulation of myofibroblasts from resident fibroblasts in breast cancer (47) . Hence, TGF-β1 acts in a coordinate and sequential manner to both stimulate proliferation of progenitors and induce their differentiation.
Another advance reported here was the development of a cancer cell-MSC recombined 3D in vitro organoid coculture model. This model requires no additional growth factors, serum substitutes, or extracellular matrix components. Organoid coculture of MSCs and tumor cells consistently formed a self-organizing organoid with a core of MSC-derived stromal cells surrounded by tumor cells. The 3D indirect coculture model permits a more detailed understanding of the complex mechanisms underlying carcinoma cell-stromal cell crosstalk.
Myofibroblasts are currently a potent target for developing antifibrotic therapies (48) . Our findings provide insights to help identify potentially specific pathways. The overall key mechanisms and contributing cell types in the formation of reactive stroma have yet been fully identified. Perturbation of pathways that produce a biologically effective mass of myofibroblasts may offer potential for the development of antifibrotic and anticancer therapies via targeting the reactive stroma microenvironment.
Materials and Methods
Isolation of Stromal Cells from Normal Human Prostate Gland. A fresh tissue core from the peripheral zone of normal prostate was obtained from 19-and 33-y-old cadaver donors following a Baylor College of Medicine Institutional Review Board approved protocol and consents. The core was cut into discs and placed in a 96-well tissue plate containing Bfs medium [DMEM; high glucose (GIBCO) supplemented with 5% (vol/vol) FBS (HyClone), 5% (vol/vol) NuSerum (Collaborative Research), 0.5 μg/mL testosterone, 5 μg/mL insulin, 100 units/mL penicillin, and 100 μg/mL streptomycin (Sigma)]. The explants were incubated at 37°C with 5% (vol/vol) CO 2 , and medium was changed every 48 h or as necessary. Stromal cells migrated out of the explant and attached to the tissue culture dish. After the cells reached confluence, the explant was moved and the cells were passaged. Cultures at passages 7-15 were used for all experiments. ) were seeded on a 12-mm round coverslip coated with poly-D-lysine/ laminin (BD BioCoat) on a 24-well culture plate (Falcon) -free Dulbecco's PBS (GIBCO). RFP-and GFP-labeled cell sorting was performed with a BD FACSAria II cell sorter.
Differential Reactive Stroma Xenograft Model. Mice were injected subcutaneously with LNCaP cells and hP-MSCs with or without Matrigel as described previously (16) . Xenografts were harvested after 3, 10, and 11 d.
Statistical Analysis. Student t test or two-way ANOVA was used to determine significance between groups. For all statistical tests, P < 0.05 was considered significant. 
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